Angiotensin II

Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...


Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...


In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan )...


The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared...


A study has tested the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart...


Entresto ( Sacubitril / Valsartan ), previously known as LCZ696 has been approved by Health Canada for the treatment of...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF...


The effect of LCZ696 on blood pressure was evaluated in patients with heart failure with preserved ejection fraction ( HFpEF...


The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure...


New data on investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction ( HFrEF ) have shown...


Novartis has announced that the Data Monitoring Committee ( DMC ) unanimously recommended early closure of the PARADIGM-HF study, indicating...


LCZ696 has shown to be superior to Ace inhibitor Enalapril ( Enapren ) on key endpoints in the largest heart...


Researchers have compared the angiotensin receptor-neprilysin inhibitor LCZ696 with Enalapril in patients who had heart failure with a reduced ejection...


Health professionals are advised that the Product Information documents for Olmesartan-containing products have been updated with a precaution for sprue-like...


FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar,...


The EMA ( European Medicines Agency ) has finalised a review of Aliskiren-containing medicines, recommending that these medicines should be...


Tribenzor is a combination of Amlodipine, Hydrochlorothiazide, and Olmesartan medoxomil. Amlodipine is a calcium channel blocker. Amlodipine is a peripheral...